December 2023



ON eNews



Welcome to our December 2023 eNews

It's the most wonderful time of the year! or at least it may feel like that when the end of year rush to complete on deals, clear the desk and 2024 budgets are submitted for approval. For over two decades, the countdown to the festive break for One Nucleus has been marked by the delivery of the Genesis conference in London. It has the ambience (deliberately) of that end of year gathering of family, friends and new entrants to the circle to catch up on what has happened, what may happen and, on some topics to disagree over healthy debate. It feels refreshingly open to new ideas being floated, challenges being laid down and above all else a great opportunity to network,



keep up-to-date and act as the genesis of new deals, collaborations and change. Look out for the release of the recorded sessions on the One Nucleus YouTube channel in the New Year! You will see some of the real time thoughts expressed and commented on if you seek out #GenesisLondon23 on social media.

Heading into another year, after the challenging year this one has proven to be for life science companies and funds raising capital, it was reassuring to hear last week of the optimism among venture investors, Pharma dealmakers and commentators anticipating an up-turn in fortunes in 1H 2024. This on the back of recent great news about companies such as Vianautis and T-Therapeutics announcing significant series A rounds. Let's hope for more successes in the 12-months ahead that we'll be sure to be talking about and celebrating going forward.

We can't always be looking in the rear-view mirror, basking in previous success or running away from failures. So looking forward, in this issue you will find details of the One Nucleus 2024 events calendar, The <u>Boston Bootcamp</u> and our inaugural <u>Annual Awards Dinner</u>– exciting new developments coming your way. As ever, you can keep up with the news from our members via our <u>website</u>, <u>LinkedIn</u> or <u>X</u> pages. The <u>News stream</u> contains numerous updates from our community.

It simply remains for me to sign off with a huge heartfelt thank-you to all who have supported the One Nucleus 2023 activities. It is very much appreciated by the One Nucleus Team how you support with financial, intellectual and moral-boosting input when called upon to enable us to support your journey to success, It's one hell of a sleigh ride we collectively take in this combined effort to improve the lives patients and those around them. Have a wonderful holiday season and we all look forward to seeing you next year.

Tony Jones, CEO, One Nucleus

Upcoming Events and Important Dates for 2024!

By Alicia Gailliez, Business Development Manager, One Nucleus

As highlighted in the Events Wrap-Up within the One Nucleus Annual Review, it is fantastic to see the participation of our network, both members and non-members in our portfolio of events. For example, the BioWednesday events have been particularly vibrant where we welcomed > 600 attendees, our conferences have been fully subscribed and the networking dinners exceptional opportunities to share experiences with peers.



As we look forward to 2024, now is the time to secure important dates in your diary for 2024 with our downloadable calendar.



Employees of One Nucleus member companies receive:

- Free access to member networking meetings
- Gold members enjoy free access to Thematic Groups and Silver members receive a 40% discount
- Up to 40% discounts on <u>ON Helix</u> and <u>Genesis</u> delegate rates
- Discounts on external events through our collaborations with key players such as EBD Group.

Upcoming Events and Important Dates for 2024!

Hitch Your Wagon to One Nucleus for Shared Success With Our Enhanced Profiling Opportunity at BIO-Europe Spring 2024



In 2023, One Nucleus had the pleasure of supporting our members with their profiling and visibility at BIO-Europe Spring in Basel, on 20-22 March and BIO- Europe in Munich, Germany on 6-8 November.

We are delighted to share testimonials from companies who have taken up the opportunity to enhance their profiling at Bio Europe on One Nucleus' stand and how it made their experience of the conference easier and the additional value it brought:

Andrew Carnegie, Head of Strategic Commercial Development, Inaphaea BioLabs

'It was a great opportunity for ValiRx, and our new cell-based services lab, Inaphaea BioLabs, to be based at the One Nucleus stand at BIO-Europe's Spring and Autumn events. We were able to add our latest flyer for our oncology patient derived cell lines at the stand, which gave us the opportunities provided by a stand, without the added expense. This also gave us a great base between partnering sessions, and the One Nucleus stand always offers excellent networking opportunities. I would absolutely recommend an enhanced profile with One Nucleus at future BIO-Europe events. Combine this with the BIO-Europe discount offered for One Nucleus members and you cannot go wrong.'

David Mead, Director of Business Development, Isogenica Limited

'Isogenica attended an energetic BIO-Europe in Munich, enjoying many productive partnering meetings, where we were able to discuss our VHH assets and our clinically proven antibody discovery services with other Biopharma companies. We appreciated the support of Tony Jones and the One Nucleus team who enhanced our profile and made additional connections with key people in relevant companies.'

Katie Headland, Business Development Director, Sygnature Discovery

'Always great to have Sygnature Discovery showcased on One Nucleus' stand for the enhanced visibility and to benefit from Tony and the team's network.'

Natassja Bush, Managing Director, Inspiralis

'I was very grateful for the enhanced profiling opportunity with One Nucleus at BIO-Europe. I attended on my own and used the One Nucleus stand as a base. I met so many people while on the stand and it increased our visibility at BIO-Europe. I would absolutely recommend it.'

Through partnership with One Nucleus partners, <u>EBD Group</u>, One Nucleus looks forward to supporting our members again next year at Bio Europe Spring 2024, taking place on 18-20 March in Barcelona, Spain.

Remember, One Nucleus members can access 12% discount off prevailing registration rates. Please contact <u>info@onenucleus.com</u> for the discount code. Register by 31 January 2024 and save up to €1035 when booking with the early bird rate.

<u>Check out further information on profiling opportunities and member discounts at BIO-Europe Spring.</u>

MARCH 18-20, 2024 BARCELONA, SPAIN



Upcoming Events and Important Dates for 2024!

Upcoming Events and Training Courses

One Nucleus Events

- 10 January | One Nucleus London Pub Social | Register
- 16 January | Access to Talent Demystifying the UK Immigration System | Register
- 13 February | **Building a Solid Foundation: A Guide to Establishing a Data Protection Program at Your Life Sciences Startup** | Register
- 12-13 March | ONLINE Building Life Science Adventures | Register
- 14 March | IP Due Diligence and How to Build a Strong IP Foundation | Register
- 21 March | Annual Awards Dinner | Sponsor

One Nucleus Training Courses

<u>View</u> our Training Course offerings and <u>upcoming 2024 training courses</u>. For more information about our in-house course offering, please contact <u>training@onenucleus.com</u>.

Industry Events

8-10 January | Member Discount Available - **Biotech Showcase™ 2024- International Partnering**Conference | Register

26 February – 1 March | Members Get Free Premium Access | **Biotechgate Digital Partnering** | Register

18-20 March | Member Discount Available - **BIO-Europe Spring® 2024** | Register (Early bird deadline 31 January)







Case Study: One Nucleus' Facility Management for Constructive Bio



By Richard Dickinson, Chief Technical Specialist, One Nucleus

One Nucleus was recently involved in Constructive Bio's transition to a new 11,000 square feet facility in Cambridge

Following transformative growth and relocation, Constructive Bio, the visionary biotech company has moved into its to new headquarters; 'The Recodery'.

Since their establishment in 2022, backed by a £12.4 million seed



investment, and under the leadership of their female CEO, Ola Wlodek, PhD EMBA and scientific guidance of professor Jason Chin as a CSO, the company cultivated a robust and growing team. Constructive Bio's journey began in a modest 2,000 sq ft workspace, but they've now expanded into the 11,000 sq ft state-of-the-art facility at Gen Two's 'The Recodery', nestled in the heart of the South Cambridge biotech cluster.



Constructive Bio's ground-breaking proprietary synthetic biology technology allows the company to introduce pharmacologically important specialised building blocks into programmable drugs.

The Recodery, its new home, mirrors the ethos of commitment to innovation and sustainability. The facility, a transformed industrial warehouse, now serves as a beacon of sustainable lab space, achieving an EPC 'A' rating. It boasts not only state-of-the-art wet lab spaces but also advanced in silico facilities for computational biology. The redesigned space includes bespoke lab

interiors with ducted fume cupboards, flexible working spaces including design-led offices, meeting rooms, and an adaptable boardroom. This environment is not just a workplace; it's a hub for pioneering biotech innovation.

The project was led internally by operations manager, Kajetan Behler, with design and implementation support provided by Richard Dickinson of One Nucleus. The facility was developed by Gen Two, and the move was organised by Restore Harrow Green.

Our Chief Technical Specialist, Richard Dickinson, has over 25 years experience as a Facilities Manager and has worked for more than 35 years in the life science sector. Richard provides project management for office and laboratory fit-outs and can help with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting.

Case Study: One Nucleus' Facility Management for Constructive Bio

Richard has worked with these Member companies in 2023:

Constructive Bio

Charm Therapeutics - 6,000 sq.ft. of labs to suite their requirement at B900 BRC.

Sosei Heptares - 5,000 sq. ft. office to labs conversion on Granta Park.

Howard Group - 9,000 sq. ft. open plan office converted to Labs and offices initially as a speculative design and then to suit Chimeris at The Works on Unity Campus

Maxion Therapeutics – Carried out dilapidations at their BRC Suites, addition benching and offices at Suite 4 The Works

Domainex – 24,500 sq. ft. of offices and lab fit out at Unity Campus.

Superdielectrics – new office and meeting room at The Emmanual Building on Chesterford Research Park.

Insmed Innovation UK – Consultancy on lab design and capital equipment for B960 on BRC

ViaNautis (SomaServe) – Looking a various locations and generating GA plans.

Broken String – Installing extraction and air con in their new Suite at The Science Village on Chesterford Research Park.

VaxEquity $-\frac{1}{2}$ a day a week FM consultancy looking after 2000 sq. ft. lab and offices on the Cambridge Science Park.

Find out more about how One Nucleus can help you find and move into new premises.



Photo with thanks to Constructive Bio

Congratulations to PrecisionLife and LifeArc, winners of the Genesis BioNewsRound Award 2023

Congratulations to the winner of the Genesis BioNewsRound Awards 2023 PrecisionLife with their announcement: PrecisionLife and LifeArc announce strategic MND/ALS partnership



Steve Gardner, PrecisionLife and Anji Miller, LifeArc with the award at Genesis 2023 Photo credit: Simon Callaghan Photography

Congratulations again to the finalists:

- Etcembly <u>Etcembly reveals world's first AI generative bispecific T cell engager with</u> picomolar affinity
- Astex Pharmaceuticals/MSD <u>Astex expands drug discovery collaboration with MSD</u>
- Maxion Therapeutics <u>Maxion Therapeutics' \$16 million Series A to drive antibody</u> development for previously untreatable ion channel and GPCR-driven diseases
- NRG Therapeutics <u>NRG Therapeutics Awarded Second \$500K Grant from The Michael J. Fox</u> Foundation to Further Progress Parkinson's Programme
- Quadram Institute/Oxford Nanopore <u>The World Health Organization supports the use of</u> targeted sequencing to detect drug resistance in tuberculosis

We look forward to more great entries in 2024!





Why We Should Win this Award! Finalists presentation sessions at Genesis 2023

Introducing ON Helix 2024 on 4 July in Cambridge...

By Alicia Gailliez, Business Development Manager, One Nucleus

ON Helix brings our network together to present and discuss developments in the tools, technologies and collaborations enabling the translation of scientific innovation into therapeutics and healthcare technologies to enhance patient outcome.

ON Helix 2023 focused on healthy ageing across the lifespan. The speakers and panellists touched upon diverse challenges including (i) a roadmap for genetic screening across different stages of life; (ii) new approaches in the development in paediatric medicines; and (iii) the "programming" of a biocluster for success. If you would like to explore the above and what other topics were covered, you can catch-up on the full recorded conference programme via the playlist on the One Nucleus YouTube channel. Reflecting on these and subsequent discussions in the year since, ON Helix 2024 builds on this conversation with the sector. Read on to discover what awaits in a programme which promises to be equally as stimulating...







Photo credit PHandB.com

The preliminary <u>conference programme</u> retains the overarching theme of 'New Horizons for Bio Innovation' as we delve again into current key technology and industry trends impacting translational research. With a new and dynamic programme format, each key topic will feature a keynote speaker, presentations from exciting companies to watch and a panel discussion. The topics will include:

- The latest developments in emerging therapeutic modalities
- The complexities of developing and applying biomarkers
- The increasing role of tech-bio
- The role of the 'global village' in translational research
- Learnings from the winners of the inaugural One Nucleus Boston Bootcamp 2024.

Introducing ON Helix 2024 on 4 July in Cambridge...

Considering the advances in the field of antibodies outlined in the Nature Cancer article Emerging new therapeutic antibody derivatives for cancer treatment, news of Moderna continuing to expand its mRNA pipeline to cancer, rare disease, and infectious disease and the challenges that Bluebird Bio faced with commercialisation of their gene therapy which led to withdrawal of the gene therapy from the European market, there is plenty to engage in in the field of emerging therapeutic modalities. There is also much to discuss regarding the evolving role of biomarker applications in therapeutics and healthcare, including leveraging biomarkers for diagnosis, monitoring and disease prediction in individual patients. Take for example evidence supporting the use of multi-omic biomarker data to understand the underlying mechanisms of complex diseases. This is explored in a study published in Human Genomics that utilised various omics data from 104 subjects to identify different omic molecules associated with risk of obesity and other complex diseases/traits. Prometheus Biosciences (recently acquired by MSD) is another compelling example where leveraging biomarker technology is being used for the treatment of inflammatory bowel disease (IBD) and other immune-mediated conditions.

We are excited to announce that registration for ON Helix 2024 is now open! The One Nucleus team looks forward to welcoming you to The Cambridge Building on Babraham Research Campus on 4 July! Sign up to secure your spot and browse our sponsor packages for further opportunities to raise your profile as an expert speaker or exhibitor.

Registration Open!

